BrainsWay to Present at Needham Virtual Healthcare Conference
Event summary
- BrainsWay to present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 8:45 AM ET.
- Company is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
- BrainsWay has three FDA-cleared indications for its Deep TMS™ platform technology.
- Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
The big picture
BrainsWay's participation in the Needham Virtual Healthcare Conference underscores its strategic focus on expanding its clinical evidence and market reach. The company's three FDA-cleared indications position it as a leader in noninvasive neurostimulation, but its success will depend on its ability to navigate regulatory landscapes and scale its technology globally. The mental health sector is increasingly turning to advanced neurostimulation treatments, making BrainsWay's role in this space critical to watch.
What we're watching
- Clinical Expansion
- The pace at which BrainsWay advances additional clinical trials in psychiatric, neurological, and addiction disorders.
- Market Penetration
- Whether BrainsWay can sustain its global awareness and access initiatives for Deep TMS.
- Regulatory Dynamics
- How future FDA approvals or regulatory shifts will affect BrainsWay's market position.
Related topics